IP Verse

Engineered Natural Killer Cells And Uses Thereof - EP3895712

The patent EP3895712 was granted to ONK Therapeutics on Jun 22, 2022. The application was originally filed on Dec 11, 2017 under application number EP21160170A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3895712

ONK THERAPEUTICS
Application Number
EP21160170A
Filing Date
Dec 11, 2017
Status
Granted And Under Opposition
May 20, 2022
Grant Date
Jun 22, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

AMMELBURGMar 21, 2023FISH & RICHARDSON PCADMISSIBLE

Patent Citations (17) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2006099875
DESCRIPTIONWO2009077857
DESCRIPTIONWO2011154453
OPPOSITIONCN105384825
OPPOSITIONUS2009285799
OPPOSITIONUS2010092489
OPPOSITIONWO2011154453
OPPOSITIONWO2014138704
OPPOSITIONWO2015142675
OPPOSITIONWO2016102687
OPPOSITIONWO2016109668
OPPOSITIONWO2016126608
OPPOSITIONWO2016201394
OPPOSITIONWO2016210293
OPPOSITIONWO2017017184
OPPOSITIONWO2017025038
OPPOSITIONWO2018104562

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- YAGITA et al., "A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation", Leukemia, vol. 14, no. 5, doi:10.1038/sj.leu.2401769, pages 922 - 30, XP055510744
OPPOSITION- CARUSO H.G. et al., Cancer Res., (20150000), vol. 75, pages 3505 - 3518-
OPPOSITION- DRENT E. et al., Haematologica, (20160000), vol. 101, no. 5, pages 616 - 625-
OPPOSITION- GHOSH A. et al., Immunol Rev, (20140100), vol. 257, no. 1-
OPPOSITION- GLIENKE W., Frontiers in Pharm., (20150212), vol. 6, no. 21, pages 1 - 7-
OPPOSITION- GRADA Z. et al., Mol Ther Nucleic Acids, (20130000), vol. 2, no. 7, page e105-
OPPOSITION- GROTH A. et al., Clin. Cancer Res., (20120000), vol. 18, no. 4, pages 1028 - 1038-
OPPOSITION- HUDECEK M. et al., Clin. Cancer Res., (20130000), vol. 19, pages 3153 - 3164-
OPPOSITION- LIU X. et al., Cancer Res., (20150000), vol. 75, pages 3596 - 3607-
OPPOSITION- SHEARD M.A. et al., J. Immunother., (20130000), vol. 36, no. 5, pages 319 - 329-
OPPOSITION- VAN DEN DONK N. et al., Blood, (20160211), vol. 127, no. 6, pages 681 - 695-
OPPOSITION- YAGITA M. et al., Leukemia, (20000000), pages 14922 - 930-
SEARCH- Shihong Yang ET AL, "Development of Retargeted CD38-Specific NK-92 Cell Line for Potential Anti-Myeloma Immunotherapy. | Blood Journal", Blood 106, (20050101), page 5104, URL: http://www.bloodjournal.org/content/106/11/5104, (20180319), XP055460459 [A] 1-15 * abstract *-
SEARCH- J CHU ET AL, "CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma", LEUKEMIA, (20130926), vol. 28, no. 4, doi:10.1038/leu.2013.279, ISSN 0887-6924, pages 917 - 927, XP055133640 [A] 1-15 * abstract *
SEARCH- E. DRENT ET AL, "Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, IT, (20160208), vol. 101, no. 5, doi:10.3324/haematol.2015.137620, ISSN 0390-6078, pages 616 - 625, XP055460439 [A] 1-15 * abstract *
SEARCH- HANS KLINGEMANN, "Are natural killer cells superior CAR drivers?", ONCOIMMUNOLOGY, (20140101), vol. 3, no. 1, doi:10.4161/onci.28147, ISSN 2162-4011, page e28147, XP055145390 [A] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents